Intravitreal anti vascular endothelial growth Factor (antiVEGF) agents such as ranibizumab are established as standard treatment for neovascular age-related macular degeneration (nAMD). For statistical reasons, most clinical trials include 1 study eye per patient. Although up to 50% of patients with nAMD in one eye may develop fellow eye involvement within 5 years 1 , few data are available on treatment outcomes in these second-affected eyes. Here were report such outcomes in patients with bilateral disease from the collaborative Fight
Retinal Blindness! (FRB!) Project 2 , which has designed and established an efficient webbased system to track outcomes of patients receiving treatment for nAMD in clinical practice.
We studied all patients from the FRB! database with bilateral nAMD in whom the second eye was diagnosed at least 2 months after the first eye and in whom both eyes had at least 12 months of follow-up data. The delay between diagnoses was chosen to ensure diagnoses were Of the total cohort of 1992 patients in the FRB! database, 28% had bilateral disease, which is similar to previous studies 3 . First and second eyes had been diagnosed with nAMD at least 2 months apart with at least 12 month follow-up data in 176 participants which formed the analysis set. Sixty-two percent of participants were female. Mean age at diagnosis of the first- The present study evaluated characteristics and outcomes in a large cohort of patients in whom both eyes were diagnosed and treated for nAMD with intravitreal ranibizumab. The within-patient, paired data allows a close examination of characteristics at diagnosis and 12 month outcomes without extraneous variation as both eyes belonged to the same patient and were treated in the same practice. Second-affected eyes had smaller lesions and better vision when they started treatment. They had slightly more injections than first affected eyes over the first 12 months of their treatment (mean 7.3 vs. 6.3) and had better VA after 12 months of treatment than first-affected eyes, even though first-affected eyes had a greater mean VA improvement. This provides strong evidence that earlier diagnosis and treatment of nAMD leads to better outcomes 4 .
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The fact that the mean VA of the first-affected eye group was 11 logMAR letters lower than the second-affected group at the index visit was expected. A recent analysis of approximately 1200 eyes with nAMD from patients treated in the United Kingdom found a 10 letter difference at presentation between first and second-affected eyes 5 . A slow decline in VA in one eye may go unnoticed if the other eye still has good vision and that patients are likely to seek help more quickly when the better (second) eye is affected. It is also likely that second eye involvement would be detected earlier during the regular visits required for treatment of the first-affected eye. This is reflected by the better vision and smaller lesion size of secondaffected eyes that we observed. The better VA at the index visit seems to be the main reason for better outcomes after 12 months of treatment since mean VA improvement of the firstaffected eye group was significantly greater than that of the second-affected group. The relatively greater improvement in first eyes is most likely due to ceiling effects in the second affected eye which had higher starting VA.
We also observed concordance of CNV lesion types developing in the first-and secondaffected eyes. This may be attributed to various factors, most likely genetic, although some discordance observed suggests that environmental factors may also contribute to lesion type.
Although not addressed in RCTs, second eye involvement is common. Hence, patient education that second eye involvement may occur and regular checks of the second eye during busy clinics in which the first-affected eye is being treated are strongly recommended in order to pick up changes early and institute treatments promptly.
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